Diacerein (TWi Biotechnology/Castle Creek Pharmaceuticals)

双醋瑞因(TWi Biotechnology/Castle Creek Pharmaceuticals)

Report date: 2025/09/19 10:17:50

Base Information

Drug NameDiacerein (TWi Biotechnology/Castle Creek Pharmaceuticals)
Drug Alias NameAC-201AC-201 Controlled release tabletAC-201 CRCCP 020CCP-020
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsDiabetes Mellitus, Type 2GoutArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTwi Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2GoutArthritis

Other Information

ATC CodeN/A
Related LinksN/A